Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin immunity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Skin immunity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-006754-31 Sponsor Protocol Number: 80101 Start Date*: 2022-03-22
    Sponsor Name:Leiden University Medical Center
    Full Title: Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers
    Medical condition: Safety and immunogenicity after revaccination with Spikevax in healthy adults who have received Comirnaty as a primary vaccine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001952-32 Sponsor Protocol Number: ACA-NETH-07-14 Start Date*: 2008-11-07
    Sponsor Name:Radboud University Nijmegen Medical Centre - Department of Dermatology
    Full Title: The effect of adalimumab on immune markers in lesional psoriatic skin.
    Medical condition: Plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001453-74 Sponsor Protocol Number: Version01.1. Start Date*: 2012-05-15
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun®
    Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003261-18 Sponsor Protocol Number: VITAL Start Date*: 2019-11-22
    Sponsor Name:
    Full Title: The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma
    Medical condition: Allergic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003369-24 Sponsor Protocol Number: ILIT-3L Start Date*: 2017-01-03
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and birch allergen or plac...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004726-28 Sponsor Protocol Number: ILIT2Linköping-Jönköping Start Date*: 2014-01-10
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and/or birch allergen one ...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002556-41 Sponsor Protocol Number: TRX 1.0 Start Date*: 2008-02-07
    Sponsor Name:Trimed Biotech GmbH
    Full Title: A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000196-23 Sponsor Protocol Number: SLO-AD-1 Italy Start Date*: 2008-10-14
    Sponsor Name:ALK-ABELLO'
    Full Title: Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive).
    Medical condition: Moderate/severe persistent Atopic Eczema (SCORAD >8 and <40)in patients sentitized to HDM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10038738 SOC
    9.1 10021428 SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002352-39 Sponsor Protocol Number: APHP220580 Start Date*: 2022-06-30
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Follow-up of Contact Persons at Risk of Monkeypox infection: prospective cohort study (MONKEY VAX)
    Medical condition: The research is proposed to people at risk of infection with the monkey pox virus (Monkey pox), and to whom an anti-pox vaccine is proposed according to the health authorities recommandations (JYNN...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001599-18 Sponsor Protocol Number: BAY 12-8039/11974 Start Date*: 2006-11-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intraven...
    Medical condition: complicated skin and skin structure Infections
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 Skin structures and soft tissue infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) BE (Completed) LV (Completed) FR (Completed) GR (Completed) IE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001591-15 Sponsor Protocol Number: NL73430.091.20 Start Date*: 2020-04-09
    Sponsor Name:Radboudumc
    Full Title: Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial.
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10047490 Virus identification and serology HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003300-12 Sponsor Protocol Number: LOKON003 Start Date*: 2019-12-20
    Sponsor Name:Lokon Pharma AB
    Full Title: A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma
    Medical condition: Malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002165-19 Sponsor Protocol Number: 20177308 Start Date*: 2019-05-10
    Sponsor Name:Medical University Vienna
    Full Title: Neo-BCC trial: Neoadjuvant treatment of difficult to resect, locally advanced basal cell carcinoma (BCC) with Talimogene laherparepvec (T-VEC)
    Medical condition: Basal cell carcinoma (BCC) is the most common malignant neoplasm in fair skinned humans (Rubin et al., 2005). Over the last decades its incidence has increased (Chinem and Miot, 2011). Especially w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017340-14 Sponsor Protocol Number: RHMCAN0700 Start Date*: 2011-07-26
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.
    Medical condition: Chronic myeloid Leukemia and acute myeloid leukemia in cytogentic remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000506-10 Sponsor Protocol Number: APHP211036 Start Date*: 2022-06-21
    Sponsor Name:Assistance Publique des Hôpitaux de Paris
    Full Title: Bariticinib in the treatment of new-onset juvenile dermatomyositis :a phase II trial
    Medical condition: New-onset juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10008521 Childhood dermatomyositis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016909-42 Sponsor Protocol Number: Start Date*: 2010-11-19
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Effect of topical imiquimod on lentigo maligna.
    Medical condition: lentigo maligna
    Disease: Version SOC Term Classification Code Term Level
    12 10024218 lentigo maligna LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002941-36 Sponsor Protocol Number: M11TCR Start Date*: 2012-04-02
    Sponsor Name:NKI-AVL
    Full Title: Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-000334-30 Sponsor Protocol Number: INT27/14 Start Date*: 2014-09-17
    Sponsor Name:Fondazione IRCCS ''IStituto Nazionale dei Tumori''
    Full Title: Immunomodulatory effect of esomeprazole antitumoral and high-dose under neoadjuvant and adjuvant in patients with melanoma in stage III. Randomized pilot study treatment vs control
    Medical condition: metastatic melanoma BLS+ and BRAF wt
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000972-40 Sponsor Protocol Number: IM101-774 Start Date*: 2020-06-09
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency
    Medical condition: Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10021449 Immunodeficiency common variable PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001770-59 Sponsor Protocol Number: BAT-2306-002-CR Start Date*: 2022-10-19
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 18:39:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA